🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings


Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.


If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.


If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies


Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

ozios_close
Mobile app

Download our mobile application and trade without restrictions. You can have all your investments in your pocket and under control wherever you go.

Your retention will contact you in a few minutes with more information about this trading strategy.
ozios_close

{{ requiredField }}

{{ validEmail }}

{{ item.name }}
{{ item.dial_code }}

{{ validPhone }}

Your message was sent
Too many tries. Try in 2 minutes

How will Pharma Giants Fight COVID in 2023?

It was COVID-19 against the world for over two years and counting, and the major players in the realm of pharma are set to triumph. As of mid-January of 2023, more than 70% of the total world population have taken at least one dose of an approved & accredited coronavirus vaccine; this amounts to over 5.5 billion vaccine shots delivered since the economy-rattling pandemic outbreak in 2020.

It was COVID-19 against the world for over two years and counting, and the major players in the realm of pharma are set to triumph. As of mid-January of 2023, more than 70% of the total world population have taken at least one dose of an approved & accredited coronavirus vaccine; this amounts to over 5.5 billion vaccine shots delivered since the economy-rattling pandemic outbreak in 2020.

There were many pharma firms in the race to create the ultimate COVID-19 vaccine and a handful of winners emerged, including Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Sinopharm, Sputnik and Novavax.

Among the winners were champions, notably Pfizer, Moderna and AstraZeneca which created trusted vaccines with high efficacy, generating immense success for the pharma giants in recent years with regards to brand exposure and of course, money bags.

COVID celebrated its three-year birthday in December of 2022 after being first identified in China’s Wuhan by birthing fresh waves of new cases across the world’s regions, with the most affected being the United States, Brazil, Japan, multiple European nations and cautious China.

Pharmaceutical behemoths have capitalized on virus resurgence, doubling up on vaccine production and delivery and enjoying considerable profits in their recent brawls with COVID.

Will coronavirus hit the breaks in 2023, and if so, what would that mean for the pharma giants?

Player 1: Prosperous Pfizer

If only a single company is to be crowned as the true victor of COVID, it would be Pfizer. The seasoned multinational pharma leader has been in the game for a long time, being the brains of some of the world’s most well-known drugs like Advil, Lyrica and Viagra as well as consumer products such as Chapstick.

The rise of COVID has produced immense success for Pfizer. The company projected record-breaking success for 2022 and has not failed to meet its high expectations, quarter after quarter. Selling billions of dollars’ worth of its COVID-19 shots and antiviral treatment pill Paxlovid, Pfizer has beat Wall Street estimates in its recent quarter:

·      Revenue: $22.6 billion

·      Net income: $8.6 billion

Pfizer generated $4.4 billion from its vaccine sales and $7.5 billion from Paxlovid in the quarter, with net income of $8.6 billion marking a 6% increase over the same quarter a year ago. The success can be largely attributed to rising COVID cases, most notably in the United States, and Pfizer has also been acquiring companies to expand its biotech business, recently securing Biohaven for $11.6 billion and Global Blood Therapeutics for $5.4 billion.

The company expects greater things ahead, raising its fiscal year 2022 guidance for revenue from $99.5 billion to $102 billion, and earnings per share of $6.40 to $6.50 for the year. [1] Other than its COVID-focused operations, Pfizer consistently makes gains from selling other pharmaceutical products, including Eliquis which is a blood thinner to treat clots and its popular pneumonia vaccine, Prevnar.

Player 2: Mighty Moderna

Moderna has been a fierce competitor in the pharmaceutical industry, despite its fresh inception in 2010. The pharma and biotech-focused Moderna has truly been mighty in its tusks with COVID, delivering over 250 million vaccine doses in the United States alone since its vaccine has been approved for use.

The Moderna vaccine has been well-received by the public and healthcare professionals, with high levels of effectiveness and safety reported. While its vaccine is highly accredited and remains so, Moderna’s performance in the 3rd fiscal quarter of 2023 was underwhelming:

·      Revenue: $3.36 billion vs. $3.53 billion expected

·      Earnings per share: $2.53 vs. $3.29 expected *

According to the company, supply chain constraints have forced Moderna to delay vaccine deliveries worth between $2 billion to $3 billion. With Moderna’s COVID vaccine being the firm’s only commercial product available, the company’s success is highly determined by national conditions of the coronavirus.

If or when COVID becomes an endemic, or in other words, regularly-occurring, Moderna expects global demand to remain resilient. Yet, the mighty Moderna lowered its 2022 sales projection from $21 billion to between $18 billion & $19 billion. Expect a turbulent year ahead!

Player 3: Ambitious AstraZeneca

AstraZeneca can be seen as the underdog in the space of COVID-19 vaccines. Despite its flagship coronavirus vaccine produced in co-operation with Oxford University being approved in 185 countries, it often gets overshadowed by the noticeable feats of Pfizer and Moderna.

The international pharmaceutical giant reported a strong business performance in the first nine months of 2022, with total revenue increasing by 37% on a year-to-year basis to a bit over $33 billion. The growth stemmed from all disease areas as well as the addition of Alexion which specializes in treating rare diseases and disorders.

According to chief executive Pascal Soriot, “AstraZeneca continues to see the benefit of sustained investment in R&D”. He also added that after such a sturdy performance, AstraZeneca increased the core EPS estimation for the full 2022 fiscal year, and that the company aims to “lead by example” in accelerating the delivery of its net zero strategy.

Technical View

Looking into the stocks of Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA) and AstraZeneca (LON: AZN), it can be seen that Moderna is the mighty stock, increasing over 900% in value since its debut on the NASDAQ stock exchange. *

Snímek obrazovky 2023-01-23 v 11.54.49

* [2]

A closer look into Pfizer & AstraZeneca stock price movement would reveal that both are quite volatile in the short-term, but are relatively stable in the long-run. This also applies to the Moderna stock, with all three stocks exhibiting positive outlooks for the long-term game. [3]

Snímek obrazovky 2023-01-23 v 11.54.58

* [4]

If only numbers mattered, PFE gained the most since its initial public offering when compared to MRNA & AZN, but AZN may be more favorable for investors which seek stability and consistent returns, since the stock has been on a predominantly-bullish ride since 2017. *

Will COVID Hit the Breaks in 2023?

When will the coronavirus pandemic end? While the concerns and seriousness of the disease may dwindle over time, that does not mean that the world is set free from the shackles of COVID. New COVID cases arise all over the world and according to Worldometer, that number can surpass 2 million fresh cases every day.

As long as mutators and variants continue to form & spread, the show will go on, and the pharma giants will witness another year of surging global demand for their vaccines, translating into profit bags to take home.

The real question may not be when will COVID end, but rather if it will end at all. If it comes an endemic just like the regular flu, vaccine sales will not halt but effectively accelerate and decelerate based on global conditions.

Adam Austera, analyst of Ozios

* Past performance is no guarantee of future results

[1,2,3,4] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guaranteeing of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.

Disclaimer:

The material herein is considered as marketing communication under the relevant laws and regulations, and as such is not a subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and should not be construed as containing investment advice, or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. The published content is intended for educational/informational purposes only. It does not take into account readers’ financial situation, personal experience or investment objectives. APME FX Trading Europe Ltd makes no representation that the information provided is accurate, current or complete; and therefore, assumes no liability for any losses arising from investments based on the supplied content. The past performance is not a guarantee of future results.

Will Rolls-Royce be the industry leader in 2023?

It was COVID-19 against the world for over two years and counting, and the major players in the realm of pharma are set to triumph. As of mid-January of 2023,...

Will Logistics Overcome Supply Chain Challenges?

It was COVID-19 against the world for over two years and counting, and the major players in the realm of pharma are set to triumph. As of mid-January of 2023,...

Is It the Right Time to Invest in Stocks?

It was COVID-19 against the world for over two years and counting, and the major players in the realm of pharma are set to triumph. As of mid-January of 2023,...
We are also available at +357 25 054 734
© 2023 APME FX TRADING EUROPE LTD

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65.38% of retail investor' accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Read our Risk Disclosures.